|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2005-12-7
|
|
pubmed:abstractText |
To determine whether a dose-dense regimen improves outcome in early breast cancer patients, we compared outcomes with the same fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapeutic regimen administered every 3 weeks (FEC21) or administered every 2 weeks (FEC14 including support with filgrastim, a granulocyte colony-stimulating factor) in a multicenter phase III randomized trial.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
pubmed-author:AitiniEnricoE,
pubmed-author:BaldiniEdittaE,
pubmed-author:BremaFulvioF,
pubmed-author:BruzziPaoloP,
pubmed-author:CanaveseGiuseppeG,
pubmed-author:CarotiCinziaC,
pubmed-author:CavazziniGiovannaG,
pubmed-author:ContuAntonioA,
pubmed-author:Del MastroLuciaL,
pubmed-author:PronzatoPaoloP,
pubmed-author:RossoRiccardoR,
pubmed-author:SertoliMario RobertoMR,
pubmed-author:TestoreFrancoF,
pubmed-author:VenturiniMarcoM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
7
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1724-33
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16333028-Adult,
pubmed-meshheading:16333028-Aged,
pubmed-meshheading:16333028-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16333028-Breast Neoplasms,
pubmed-meshheading:16333028-Chemotherapy, Adjuvant,
pubmed-meshheading:16333028-Confidence Intervals,
pubmed-meshheading:16333028-Cyclophosphamide,
pubmed-meshheading:16333028-Disease-Free Survival,
pubmed-meshheading:16333028-Dose-Response Relationship, Drug,
pubmed-meshheading:16333028-Drug Administration Schedule,
pubmed-meshheading:16333028-Epirubicin,
pubmed-meshheading:16333028-Female,
pubmed-meshheading:16333028-Fluorouracil,
pubmed-meshheading:16333028-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:16333028-Humans,
pubmed-meshheading:16333028-Infusions, Intravenous,
pubmed-meshheading:16333028-Italy,
pubmed-meshheading:16333028-Middle Aged,
pubmed-meshheading:16333028-Multivariate Analysis,
pubmed-meshheading:16333028-Odds Ratio,
pubmed-meshheading:16333028-Recombinant Proteins,
pubmed-meshheading:16333028-Risk Factors,
pubmed-meshheading:16333028-Survival Analysis,
pubmed-meshheading:16333028-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
|
|
pubmed:affiliation |
Institution of Oncologia Medica, Sperimentazioni Cliniche Controllate Istituto Nazionale per la Ricerca sul Cancro, Genova (PB), Italy. marco.venturini@istge.it
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
